We develop drug candidates to advance into the clinic with pharmaceutical partners

We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities.

Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.

Our Pipeline

We are inviting pharmaceutical partners to take all current and future candidates to clinical success.

INDICATION
RESEARCH
PRECLINICAL
PHASE I
PHASE II
Therapies for complement disorders
C3 glomerulopathy (C3G)
Compleva FH/CPV-104 (natural complement regulator)
Enzyme replacement therapies
Fabry disease
Repleva AGAL/RPV-001 (glyco-improved Fabry-ERT)

Which product can we develop with you?

We look forward to hearing from you!

eleva GmbH
Hans-Bunte-Str. 19
79108 Freiburg
Germany

Phone: +49 761 470 99 0
hello@elevabiologics.com

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.

I consent to the processing of my personal data for the purpose of establishing contact in accordance with Article 6 paragraph 1 lit a of the Basic Data Protection Regulation (DSGVO).

In accordance with Article 13 of the Basic Data Protection Regulation (DSGVO), we would like to provide you with comprehensive information about the processing of your personal data. You can read all relevant information in our data protection policy.